Agenus Inc (AGEN)

$4.39 -0.13 (-2.88%)
Market Cap 144.03M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -219.61%
Debt to Equity Ratio -0.10
Volume 245,676
Avg Vol 989,038
Day's Range N/A - N/A
Shares Out 31.86M
Stochastic %K 53%
Beta 1.62
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
docBNM
docBNM Aug. 25 at 8:07 PM
$AGEN any legit expectations for Wednesday ? Nothing moves the needle with this stock price it seems. Hopium all around.
0 · Reply
BakerBrother
BakerBrother Aug. 25 at 4:07 PM
$AGEN we have achieved the success that we wanted to achieve in curing some of the cancer patients that would be otherwise incurable and we have not yet achieved the financial success but it's inevitable that this will come next.
1 · Reply
Stefman9
Stefman9 Aug. 25 at 3:10 PM
$AGEN I have lost confidence in Garo, so I am now heavily holding AGEN and XLO. Incase Garo continues to try and go it alone depleting Shareholder equity. Very sad situation with him holding one of the best drugs. Horrible management team.
3 · Reply
Biotechguy21
Biotechguy21 Aug. 25 at 2:43 PM
$AGEN how much money has been wasted??? 🤡🤡🤡🤡
0 · Reply
Garo_is_a_Con_Man
Garo_is_a_Con_Man Aug. 25 at 2:28 PM
$AGEN It is my opinion; Garo the Con Man used his Weekly Pump Sessions to make unsubstantiated claims to entice Investors into investing. I believe this was Fraudulent and I believe Garo the Con Man should be in Prison.
0 · Reply
Biotechguy21
Biotechguy21 Aug. 25 at 2:15 PM
$AGEN this pos will only go lower and much lower soon. stay tuned 🤡🤡😂😂🤡🤡😂😂👀👀👀👀
0 · Reply
weichsel1
weichsel1 Aug. 25 at 4:17 AM
$AGEN didn’t management claim four deals close to closing back in April? What happened to the other three? Any word on Zydus closing?
1 · Reply
neversurrender2024
neversurrender2024 Aug. 23 at 8:55 PM
$AGEN after blowing 2.2 billion over thirty years garos now starting to sell $AGEN assets.dear stuck holders "you will own nothing and be happy"!
0 · Reply
CrypticTrigger
CrypticTrigger Aug. 23 at 4:58 AM
$AGEN Immuno-oncology company with clinical setbacks and restructuring efforts underway
1 · Reply
Garo_is_a_Con_Man
Garo_is_a_Con_Man Aug. 22 at 5:58 PM
$AGEN If America wants to Clean Up Fraud, we need to put ALL Fraudsters in Prison. No Fines. Just Prison. Garo the Con Man should be in Prison.
0 · Reply
Latest News on AGEN
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 19, 2025, 7:30 AM EDT - 6 days ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Aug 11, 2025, 7:30 AM EDT - 14 days ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 25 days ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 4 weeks ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 7 weeks ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 2 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 2 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 2 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 3 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 3 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 3 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 3 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 3 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 3 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 29, 2025, 7:30 AM EDT - 4 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 28, 2025, 3:30 PM EDT - 4 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 25, 2025, 1:05 PM EDT - 4 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 4 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 5 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 5 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 5 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 6 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 6 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 25, 2025, 8:26 AM EST - 6 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:33 AM EST - 6 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 6 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 6 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 29, 2025, 12:37 PM EST - 7 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Jan 22, 2025, 2:48 PM EST - 7 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 18, 2024, 7:30 AM EST - 8 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Dec 5, 2024, 7:30 AM EST - 9 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 27, 2024, 8:15 AM EST - 9 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 10 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 12, 2024, 7:00 AM EST - 10 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 7, 2024, 10:00 AM EST - 10 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 5, 2024, 7:30 AM EST - 10 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 10 months ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 10 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

docBNM
docBNM Aug. 25 at 8:07 PM
$AGEN any legit expectations for Wednesday ? Nothing moves the needle with this stock price it seems. Hopium all around.
0 · Reply
BakerBrother
BakerBrother Aug. 25 at 4:07 PM
$AGEN we have achieved the success that we wanted to achieve in curing some of the cancer patients that would be otherwise incurable and we have not yet achieved the financial success but it's inevitable that this will come next.
1 · Reply
Stefman9
Stefman9 Aug. 25 at 3:10 PM
$AGEN I have lost confidence in Garo, so I am now heavily holding AGEN and XLO. Incase Garo continues to try and go it alone depleting Shareholder equity. Very sad situation with him holding one of the best drugs. Horrible management team.
3 · Reply
Biotechguy21
Biotechguy21 Aug. 25 at 2:43 PM
$AGEN how much money has been wasted??? 🤡🤡🤡🤡
0 · Reply
Garo_is_a_Con_Man
Garo_is_a_Con_Man Aug. 25 at 2:28 PM
$AGEN It is my opinion; Garo the Con Man used his Weekly Pump Sessions to make unsubstantiated claims to entice Investors into investing. I believe this was Fraudulent and I believe Garo the Con Man should be in Prison.
0 · Reply
Biotechguy21
Biotechguy21 Aug. 25 at 2:15 PM
$AGEN this pos will only go lower and much lower soon. stay tuned 🤡🤡😂😂🤡🤡😂😂👀👀👀👀
0 · Reply
weichsel1
weichsel1 Aug. 25 at 4:17 AM
$AGEN didn’t management claim four deals close to closing back in April? What happened to the other three? Any word on Zydus closing?
1 · Reply
neversurrender2024
neversurrender2024 Aug. 23 at 8:55 PM
$AGEN after blowing 2.2 billion over thirty years garos now starting to sell $AGEN assets.dear stuck holders "you will own nothing and be happy"!
0 · Reply
CrypticTrigger
CrypticTrigger Aug. 23 at 4:58 AM
$AGEN Immuno-oncology company with clinical setbacks and restructuring efforts underway
1 · Reply
Garo_is_a_Con_Man
Garo_is_a_Con_Man Aug. 22 at 5:58 PM
$AGEN If America wants to Clean Up Fraud, we need to put ALL Fraudsters in Prison. No Fines. Just Prison. Garo the Con Man should be in Prison.
0 · Reply
joechuck71
joechuck71 Aug. 22 at 2:45 PM
$AGEN wow holding it back
0 · Reply
Sir_Robert
Sir_Robert Aug. 22 at 1:28 PM
$AGEN I see that both Drs. Nicholas DeVito and Marwan Fakih are running trials for Vilastobart combination for MSS CRC as well as for Bot Bal. The ORR for Vilastobart is 26% although for fewer numbers and earlier trial setting. Would love to know what these two doctors think about the comparative efficacy of the two treatments. Question should definitely be put to DeVito during meeting on 27th.
3 · Reply
Cure4Cancer
Cure4Cancer Aug. 22 at 2:41 AM
$AGEN Still fighting
0 · Reply
manny11419
manny11419 Aug. 21 at 8:23 PM
$AGEN Some has commented that Agen should go after Sarcoma, this low hanging fruit could enabled off label prescription..problem is that Agenus must run SOC against the combo. Recently, the FDA ok a cell therapy regimen for certain Sarcomas, which is very expensive. I believe the treatment cost several hundreds of thousands. Adapimmune (Adap), which I follow for a decade developed the treatment. Amazingly, Adapt, is selling for 6 cents, despite two BTD's from the FDA. I recently pick up some..some of you guys looking for idea, may want to take a look.
2 · Reply
Scooter0732
Scooter0732 Aug. 21 at 6:56 PM
$AGEN Makary made some comments on his podcast there will be announcements soon re NPRV. Why do I get the sinking feeling like Dostarlimab or Ipi/Nivo in Neo dMMR will get the nod instead of Bot/Bal?
5 · Reply
neversurrender2024
neversurrender2024 Aug. 21 at 4:03 PM
$INKT not only do you have the atm to worry about but it looks like garos selling shares to keep $AGEN afloat! its going lower folks!
1 · Reply
neversurrender2024
neversurrender2024 Aug. 21 at 3:46 PM
$AGEN so agenus now owns less than 50% of $INKT before garo spun it off and stuffed his pockets we owned it all....
1 · Reply
neversurrender2024
neversurrender2024 Aug. 21 at 3:12 PM
$AGEN good morning stuck holders ! are you ready for the unveiling?
0 · Reply
JohnG8
JohnG8 Aug. 21 at 2:40 PM
$AGEN is there anybody here who can come up with a good reason why they have delayed P3 by 18 months? Is there an advantage that I’m not seeing? Or is it just the incompetence that I’m assuming it is?
5 · Reply
docBNM
docBNM Aug. 21 at 2:06 PM
$AGEN FDA has approved 14 novel therapies in 2025 👇 These include breakthrough treatments in areas like cancer, neurofibromatosis, pain management, and rare diseases. Novel drugs are therapies never before approved or marketed in the U.S., representing true innovation in medicine. 📉 For perspective: 2021: 50 approvals 2022: 37 2023: 55 2024: 50 2025: 13 (so far) WTF ??!!?!?!?! 📊 Source: FDA, Sylvain Plagella
1 · Reply
docBNM
docBNM Aug. 21 at 1:34 PM
$AGEN nothing seems to move this POS. I don't see that changing on the 27th, which will be just more of the same ole $HIT. We need something more definitive, like a BP partner with some real $$$
1 · Reply
Jake71440
Jake71440 Aug. 21 at 1:25 PM
$AGEN "We hereby now inform that ZPUI has incorporated a wholly owned subsidiary in the name of a Zylidac Bio LLC on July 11, 2025. Zylidac will be acquiring the Target Assets of Agenus" Zydus Incorporation of a wholly owned subsidiary in the United States of America
3 · Reply